EGFR and non-small cell lung carcinoma: The outcome from this phase III trial showed that dacomitinib significantly improved PFS compared to gefitinib in first-line treatment of patients with EGFR-mutation-positive NSCLC, with median PFS of 14.7 vs 9.2 months, respectively (hazard ratio 0.59, 95% confidence interval, CI: 0.47-0.74, p<0.0001).